Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab

Critical Reviews in Oncology/Hematology

Volumn 74, Issue 3, 2010, Pages 193-202

  Rodríguez, Javier ^a   Viúdez, Antonio ^a   Ponz Sarvisé, Mariano ^a   Gil Aldea, Isabel ^a   Chopitea, Ana ^a   García Foncillas, Jesús ^a   Gil Bazo, Ignacio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Advanced colorectal cancer; Biomarkers; EGFR; Panitumumab; Targeted therapy

Indexed keywords

AMG 479; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STAT PROTEIN; TRASTUZUMAB;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ANAPHYLAXIS; ANOREXIA; BINDING AFFINITY; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; GASTROINTESTINAL DISEASE; GENE AMPLIFICATION; HAIR DISEASE; HIRSUTISM; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; LACRIMATION DISORDER; LUNG FIBROSIS; METASTASIS POTENTIAL; MONOTHERAPY; NAIL COLOR DEFECT; NAIL DISEASE; NAIL INFECTION; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ONCHORRHEXIS; ONYCHOLYSIS; OVERALL SURVIVAL; PARONYCHIA; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PRURITUS; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN EXFOLIATION; SKIN TOXICITY; SOLID TUMOR; TELANGIECTASIA; TUMOR REGRESSION; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; HUMANS;

EID: 77953364197     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.07.005     Document Type: Review

References (90)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004, 350:2050-2059.
3. O'Connell M.J. Current status of adjuvant therapy for colorectal cancer. Oncology (Williston Park) 2004, 18:751-755.
4. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
5. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
6. Bengtsson G., Carlsson G., Hafström L., Jönsson P.E. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981, 141:586-589.
7. de Brauw L.M., van de Velde C.J., Bouwhuis-Hoogerwerf M.L., Zwaveling A. Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 1987, 34:81-86.
8. Gaffe B.M., Donegan W.L., Watson F., Sprat J.S. Factor influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 1969, 127:1-11.
9. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
10. Giusti R.M., Shastri K.A., Cohen M.H., Keegan P., Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007, 12:577-583.
11. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
12. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
13. Scaltriti M., Baselga J. The epidermal growth receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272.
14. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744.
15. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
16. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25:2171-2177.
17. Saltz L.B., Meropol N.J., Loehrer P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
18. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
19. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metatatic colorectal cancer: the Crystal trial. J Clin Oncol 2007, 25. [abstract 4000].
20. Bokemeyer C., Bondarenko I., Makhson A., et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study. J Clin Oncol 2007, 25. [abstract 4035].
21. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
22. Ryan Q., Ibrahim A., Cohen M.H., et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008, 13:1114-1119.
23. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
24. Gridelli C., Bareschino M.A., Schettino C., et al. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007, 12:840-849.
25. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
26. Cohenuram M., Saif M.W. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007, 18:7-15.
27. Freeman D., McDorman K., Bush T., et al. Mono and combination-therapeutic activity of panitumumab (ABX-EGF) on human A431 epidermoid and HT-29 colon carcinoma xenografts; correlation with pharmacodynamic parameters. Proc Amer Assoc Cancer Res 2004, 27-31.
28. Mendez M.J., Green L.L., Corvalan J.R., et al. Functional transplant of magabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997, 15:146-156.
29. Fan Z., Baselga J., Masui H., Maendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53:4637-4642.
30. Yang X.D., Jia X.C., Corvalan J.R., et al. Erradication of established tumors by a fully human monoclonal to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999, 59:1236-1243.
31. Jia X.C., Corvalan J.R.F., Zhang L. Inhibition of vascular endothelial cell growth factor and interleukin-8 production in tumor and endothelial cell lines by a fully human monoclonal antibody to epidermal groth factor receptor. Proc Amer Assoc Cancer Res 2000, 290.
32. Yang X.D., Corvalan J.R.F., Wang P. Inhibition of human cancer growth by ABX-EGF, a fully human anti-EGF receptor monoclonal antibody. Proc Am Assoc Cancer Res 2000, 530.
33. Lynch D.H., Yang X.D. Therapeutic potential of ABX-EGF: a fully antiepidermal growth factor reeptor monoclonal antibody for cancer treatment. Semin Oncol 2002, 29:47-50.
34. Arends R., Yang B., Schwab G., et al. Flexible dosing schedules of panitumumab in cancer patients. J Clin Oncol 2005, 23. [abstract 3089].
35. Weiner L.M., Belldegrun A., Rowinsky E., et al. Updated results from a dose and schedule study of Panitumumab monotherapy in patients with advanced solid malignancies. J Clin Oncol 2005, 23. [abstract 3059].
36. Peeters M., Van Cutsem E., Hecht J.R., et al. Efficacy and safety of panitumumab across five clinical studies in patients with metastatic colorectal cancer. J Clin Oncol 2007, [Gastrointestinal cancers symposium, abstract 336].
37. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
38. Amado R.G., Wolf M., Peeters M., et al. Wild-type Kras is required for Panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
39. Van Cutsem E., Siena S., Humblet Y.S., et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008, 19:92-98.
40. Hecht J., Berlin J., Malik I., et al. Panitumumab therapy with IFL in metastatic colorectal cancer patients: a pharmacokinetic analysis results. J Clin Oncol 2005, [Gastrointestinal cancers symposium, abstract 259].
41. Berlin J., Posey J., Tchekmedyian S., et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007, 6:427-432.
42. Peeters M., Wilson G., Hotko Y., et al. Phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer (mCRC): preliminary safety results. J Clin Oncol 2008, [Gastrointestinal cancers symposium, abstract 335].
43. Douillard J., Siena S., Cassidy J., et al. Phase III study (PRIME/20050203) of panitumumab with FOLFOX4 compared to FOLFOX4 alone in patients with previously untreated metastatic colorectal cancer (mCRC): preliminary safety data results. J Clin Oncol 2008, [Gastrointestinal cancers symposium, abstract 443].
44. Drelich D.A., Rose L., Ramirez M., Jacobs M., Mitchell E. Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer from three clinical studies. J Clin Oncol 2007, 25. [abstract 14551].
45. Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16:1425-1433.
46. Peeters M., Van Cutsem E., Berlin J., et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor, in patients with metastatic colorectal cancer across clinical trials. J Clin Oncol 2007, 25. [abstract 4138].
47. Giusti R.M., Shastri K., Pilaro A.M., et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008, 14(March (5)):1296-1302.
48. Anon. Vectibix (panitumumab) prescribing information. (v3, rev October 2007) Amgen Inc.: Thousand Oaks, CA. Available at: (accessed 10.03.2008). http://www.vectibix.com/pdfs/misc/vectibix_pi.pdf.
49. Perez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 2005, 22:5235-5241.
50. Berlin J., Van Cutsem E., Peeters M., et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer. A pooled analysis of five clinical trials. J Clin Oncol 2007, 25. [abstract 4134].
51. Figlin R.A., Belldegrun A.S., Crawford J., et al. ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with advanced cancer. Phase I clinical results. J Clin Oncol 2002, 21. [abstract 35].
52. Hecht J.R., Patnaik A., Berlin J., et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007, 110:980-988.
53. Mitchell E.P., Hercht J.R., Baranda J., et al. Panitumumab activity in metastatic colorectal cancer patients with low or negative tumor epidermal growth factor receptor levels: an updated analysis. J Clin Oncol 2007, 25. [abstract 4082].
54. Scartozzi M., Bearzi I., Berardi R., et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004, 22:4772-4778.
55. Atkins D., Reiffen K.A., Tegtmeier C.L., et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004, 52:893-901.
56. Graus-Porta D., Beerli R., Daly J., Hynes N. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J 1997, 16:1647-1655.
57. Tzahar E., Waterman H., Chen X., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287.
58. Lenferink A., Pinkas-Kramarski R., van de Poll M., et al. Differential endocytic of homo- and hetero-dimeric ErbB tyrosine kinases confers signalling superiority to receptor heterodimers. EMBO J 1998, 17:3385-3397.
59. Emlet D.R., Schwartz R., Brown K.A., et al. HER-2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer 2006, 94:1144-1153.
60. Johnston S., Trudeau M., Kaufman B., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 in advanced inflammatory breast cancer with Lapatinib monotherapy. J Clin Oncol 2008, 26:1066-1072.
61. Bos J.L., Fearon E.R., Hamilton S.R., et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327:293-297.
62. Freeman D., Amado R., Wolf M., et al. Efficacy of Panitumumab monotherapy in relation to KRAS mutational status for treating metastatic colorectal cancer from four clinical studies. J Clin Oncol 2008, [abstract 47].
63. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required fo response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
64. Merlin J.L., Perkins G., Lievre A., et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer. J Clin Oncol 2008, 26. [abstract 4126].
65. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number of epidermal growth factor receptor and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
66. Lièvre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
67. Sartore-Bianchi A., Moroni M., Veronese S., et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with Panitumumab. J Clin Oncol 2007, 25:3238-3245.
68. Carcereny E., Castellvi-Bel S., Alonso V., et al. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer treated with cetuximab and panitumumab. J Clin Oncol 2008, 26. [abstract 4124].
69. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370.
70. Petit A.M.V., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151:1523-1530.
71. Ciardiello F., Bianco R., Daminao V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000, 6:3739-3747.
72. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
73. Punt C.J., Tol J., Rodenburg C.J., et al. Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of yhe Dutch Colorectal Cancer Group. J Clin Oncol 2008, 26(Suppl.):180s. [abstract LBA 4011].
74. Schwartzberg L.S., Hurwitz H., Stephenson J., et al. Safety and pharmacokinetics of AMG706 with Panitumumab plus FOLFIRI or FOLFOX for the treatment of patients with metastatic colorectal cancer. J Clin Oncol 2007, 25. [abstract 4081].
75. Jones H.E., Goddard L., Gee J.M.W., et al. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 2004, 11:1-22.
76. Beltran P.J., Mitchell P., Moody G., et al. AMG 479, a fully human anti IGF-1 receptor antibody, inhibits P3IK/Akt signalling and exerts potent antitumor effects in combination with EGFR inhibitors in pancreatic xenograft models. J Clin Oncol 2007, [Gastrointestinal cancers symposium, abstract 208].
77. Sarantopoulos J., Mita A.C., Mulay M., et al. A phase Ib of AMG479, a type 1 insulin-like growth factor receptor antibody in combination with Panitumumab or Gemcitabine. J Clin Oncol 2008, 26. [abstract 3583].
78. Freeman D., Sun J., Bass R., et al. Panitumumab and cetuximab epitope mapping and in vitro activity. J Clin Oncol 2008, 26. [abstract 14536].
79. Langerak A.D., Mitchell E., Cheema G., River L., Shing M. Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer patients intolerant to cetuximab. J Clin Oncol 2007, 25. [abstract 14579].
80. Helbling D., Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007, 18:963-964.
81. Asmis T.R., Shah M.A., Haviland D., Kemeny N. Panitumumab with or without chemotherapy on metastatic colorectal cancer: safety and unusual activity, even following progression on Cetuximab. J Clin Oncol 2008, [Gastrointestinal cancers symposium, abstract 484].
82. Frattini M., Saletti P., Romagnani E., et al. PTEN loss of expression predicts Cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-1145.
83. Scartozzi M., Bearzi I., Pierantoni C., et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007, 25:3930-3935.
84. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
85. Grunwald V., Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003, 95:851-867.
86. Boedigiemer M., Freeman D., Fitzpatrick D., et al. Gene expression profiles can predict panitumumab monotherapy responsiveness in xenograft models: a balanced approach. Proc Amer Assoc Cancer Res 2005, 46. [abstract 1].
87. Liotta L.A., Espina V., Mehta A.I., et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003, 3:317-325.
88. Bencardino K., Ronzoni M., Manzoni M., et al. In vivo biological effects of Panitumumab plus chemotherapy in advanced colorectal cancer patients. J Clin Oncol 2008, 26. [abstract 14576].
89. Hendlisz A., Marechal R., Durbecq V., et al. Modulation and prognostic value of epidermal growth factor receptor expression in circulating tumour cells during chemotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26. [abstract 15038].
90. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.